

REPORT 6 OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (A-10)
Use of Electronic Cigarettes in Smoking Cessation Programs
Reference Committee D

EXECUTIVE SUMMARY

Objective. This report reviews current AMA Policy related to electronic cigarettes (e-cigarettes), the manufacture and characteristics of e-cigarettes, current regulations and the potential health impacts of e-cigarettes, and their potential role in smoking cessation.

Methods. Literature searches for review articles were conducted in the PubMed database and the Cochrane Database of Systematic Reviews using the search terms “electronic cigarettes,” “e-cigarettes,” “smokeless cigarettes,” “tobacco-free cigarettes,” “nicotine addiction,” “nicotine inhaler,” and “nicotine spray,” in the article title and/or abstract. Web sites managed by federal agencies and applicable professional organizations also were reviewed for relevant information. Commercial Web sites of e-cigarette manufacturers and distributors and comments from concerned public health professionals and submissions regarding FDA regulatory powers over e-cigarettes also were consulted. Additional articles were identified by reviewing the reference lists of pertinent publications.

Results. E-cigarettes are non-flammable devices that deliver synthetic or tobacco-derived nicotine; they are similar in size, shape, and usage to their leaf tobacco counterparts. They are available worldwide through the Internet or increasingly in retail outlets. Little independent research has been conducted into their ingredients and health impacts, but they are commercially promoted by vendors and some health harm reduction advocates as a safe alternative to cigarettes, and in some instances, as smoking cessation aids or for cutting down smoking by those not wanting to quit or eliminate their nicotine dependence. However, manufacturers of e-cigarettes have not submitted the requisite applications for FDA approval of these products for smoking cessation. While e-cigarettes may produce or maintain nicotine dependence, the vapor released contains polyethylene glycol (PG), which looks like cigarette smoke (also used for theatrical smoke) and is also an FDA-approved food additive commonly found in deodorants, moisturizing lotions, toothpastes; pharmaceutical products, including some inhalers; and fat-free dairy products.

Because E-cigarettes have not been thoroughly tested, one cannot conclude that they do not produce any harmful products, even if they produce fewer dangerous substances than conventional cigarettes. In fact, analysis of two brands of e-cigarettes found detectable levels of known carcinogens and toxic chemicals (i.e., diethylene glycol, an ingredient used in antifreeze, small amounts of tobacco-specific nitrosamines, and certain other tobacco-specific impurities that may be harmful). To date, most research on e-cigarette ingredients, safety, health effects, and use by current smokers has been funded by manufacturers. Independent studies by the FDA and Demokritas, a publicly funded research institute based in Greece, raised questions about the actual ingredients found in commercial e-cigarettes, consistency of nicotine levels, and quality control in their manufacture. Whether the FDA will have regulatory control, and over which aspects, remains to be determined.

Conclusions. E-cigarettes might present an effective alternative to leaf tobacco use for some smokers, but clinical testing, larger population studies, and full analyses of their ingredients and manufacturing processes need to be conducted before their safety, viability, and impacts can be determined as either clinical tools or as widely available, effective alternatives to tobacco use. Whether e-cigarettes can safely help people quit smoking also is unknown, but with their fruit and candy flavors, they have a clear potential to entice new smokers.

REPORT OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH

CSAPH Report 6-A-10

Subject: Use of Electronic Cigarettes in Smoking Cessation Programs

Presented by: C. Alvin Head, MD, Chair

Referred to: Reference Committee D
(Diana E. Ramos, MD, Chair)

1 INTRODUCTION

2
3 This report is being written in response to Resolution 420 (A-09), "Study of Appropriate Use of
4 Electronic Cigarettes in Smoking Cessation Programs," (Policy D-490.975, AMA Data Base),
5 introduced by the American Association of Public Health Physicians and adopted by the House of
6 Delegates. Resolution 420 asks the Council to study the available evidence and develop
7 recommendations on the appropriate use of electronic cigarettes (e-cigarettes) in smoking cessation
8 programs. Accordingly, this report reviews current AMA Policy related to e-cigarettes, the
9 manufacture and characteristics of e-cigarettes, current regulations and the potential health impacts
10 of these products, and their potential role in smoking cessation.

11
12 METHODS

13
14 Literature searches for review articles were conducted in the PubMed database and the Cochrane
15 Database of Systematic Reviews using the search terms "electronic cigarettes," "e-cigarettes,"
16 "smokeless cigarettes," "tobacco-free cigarettes," "nicotine addiction," "nicotine inhaler," "nicotine
17 spray," in the article title and/or abstract. Web sites managed by federal agencies and applicable
18 professional organizations also were reviewed for relevant information. Commercial Web sites of
19 e-cigarette manufacturers and distributors and comments from concerned public health
20 professionals and submissions regarding the Federal Drug Administration's (FDA) regulatory
21 powers over e-cigarettes also were examined. Additional articles were identified by reviewing the
22 reference lists of pertinent publications.

23
24 CURRENT AMA POLICY RELATED TO E-CIGARETTES

25
26 Current AMA policy does not specifically address e-cigarettes; however, Policy H-495.985 (AMA
27 Policy Database) addresses the use of snuff and chewing tobacco and contains language relevant to
28 e-cigarettes. This policy "objects strongly to the introduction of "smokeless" cigarettes" and also
29 "opposes the use of smokeless tobacco products by persons of all ages." Policy H-495.988
30 addresses the production and dissemination of all tobacco products and reaffirms the AMA position
31 that all tobacco products are harmful to health; there is no such thing as a safe cigarette; tobacco is
32 a raw form of the drug nicotine; and tobacco products are delivery devices for an addictive
33 substance. This policy also supports the view that the FDA should continue to have broad powers
34 and authority to regulate tobacco products, including their manufacture, sale, distribution, and
35 marketing, and urges Congress to pass legislation to phase in the production of less hazardous and
36 less toxic tobacco. Furthermore, the FDA and other appropriate agencies should conduct or fund

1 research on how tobacco products might be modified to facilitate cessation of use, including
2 elimination of nicotine and elimination of additives (e.g., ammonia) that enhance addictiveness.
3 With regard to smoking cessation, Policy H-490.911 supports smoking cessation programs and
4 seeks the passage of legislation that makes all workplaces smoke free. Policy H-490.917 outlines
5 physician responsibilities for smoking cessation and advocates the use of surveillance approaches
6 to measure changes in the use of alternative nicotine delivery systems. Finally, Policy D-490.977
7 urges physicians and health organizations to avoid providing patients and consumers with
8 information or materials on tobacco that come from tobacco companies or other groups aligned
9 with the tobacco industry.

10 USE OF ALTERNATIVES TO SMOKED TOBACCO IN SMOKING CESSATION

11 The key recommendations of the U.S. Department of Health and Human Services' Public Health
12 Service clinical practice guidelines on treating tobacco use and dependence¹ recognize seven first-
13 line medications (of which five contain nicotine) for use by patients attempting to quit smoking.
14 Although counseling and medications are both effective in treating tobacco dependence, the
15 combined use of counseling and medication is more effective than either alone. Nicotine-
16 containing medications (usually referred to under the rubric of Nicotine Replacement Therapy or
17 NRT) are available in five delivery mechanisms including transdermal patch, chewing gum, nasal
18 spray, lozenge, and inhaler formulations. The non-nicotine medications approved for smoking
19 cessation are bupropion SR and varenicline.

20 ELECTRONIC CIGARETTES

21 *Description*

22 E-cigarettes and cigars (e-cigars) are non-flammable nicotine delivery devices that are roughly the
23 same size and shape as their leaf tobacco counterparts but do not (apparently) use tobacco products.
24 *Eclipse*®, produced and marketed by R.J. Reynolds Tobacco Company, also is a nicotine delivery
25 device that releases nicotine via heating rather than burning but, unlike e-cigarettes, the primary
26 ingredients are tobacco and tobacco products. The nicotine in e-cigarettes is either synthetic
27 (chemically developed) or is extracted from tobacco. E-cigarettes consist of three integrated parts
28 contained in a stainless steel shell: the mouthpiece (or nicotine cartridge), the atomizer chamber (or
29 vaporizer), and a smart chip lithium ion battery.²

30 Typically, a disposable filter holds a cartridge containing synthetic nicotine dissolved in propylene
31 glycol, water, and flavorings. In tests conducted by the FDA's Division of Pharmaceutical
32 Analysis on two brands of e-cigarettes, additional ingredients were detected including diethylene
33 glycol in one cartridge (a component of antifreeze and toxic to humans) and tobacco-specific
34 nitrosamines (a known carcinogen) in half of the samples.³ This is very concerning and adds to the
35 premise that such items should be closely regulated. When the entire unit is assembled, the user
36 creates an inhaling motion which activates the battery via pressure sensors. The battery powers the
37 vaporizer, and the vaporizer heats the liquid housed in the mouthpiece. As such, the electronic
38 cigarette is a delivery device for the addictive substance nicotine. The vapor released is
39 polyethylene glycol (PG), which looks like cigarette smoke (also used for theatrical smoke) and is
40 also an FDA-approved food additive. The volume released varies by brand, but when inhaled feels
41 like cigarette smoke to users. Unlike tobacco smoke, the vapor quickly evaporates, leaves no
42 remaining odor, but the secondhand smoke may still be irritating.

43 Compared with conventional cigarettes, which last for about fifteen puffs, e-cigarettes can sustain
44 from 150 to 300 puffs, the equivalent of one-half to one pack of cigarettes. The cartridges vary in

1 nicotine strength, being characterized as “zero,” low, medium, or high.^{4,5} Disposable, non-refillable
2 versions, equivalent to one or two packs of cigarettes, also are available.

3
4 *Sales and Marketing*

5
6 E-cigarettes were invented by an employee (Hon Lik) of a Chinese electronics company (Ruyan)
7 headquartered in Beijing, which began marketing them in 2004. The Ruyan Group remains the
8 leading manufacturer of e-cigarettes (sold as Ruyan® e-cigarettes), but additional manufacturers
9 using similar devices have subsequently entered the market, offering their products worldwide via
10 the Internet, in shopping malls, and via distributors. Ruyan claims it sold 300,000 devices in 2008,
11 and two major U.S. e-cigarette importers claimed sales totaling 735,000 units.^{6,7} U.S. sales of other
12 products are not known, although an advertisement for the “Easy As Step 1,2,3” package of
13 e-cigarettes says “millions of smokers have become smoke-free” using the package.⁵ Prices for the
14 devices (a charger, rechargeable battery, and five nicotine cartridges) range from about \$80 to \$150
15 with packages of replaceable cartridges, each good for several uses, costing \$10 to \$15 or the
16 equivalent of 1 to 1.5 packs of cigarettes.⁸

17
18 **HEALTH IMPACTS**

19
20 In general, little independent research has been conducted into the ingredients of commercially
21 available e-cigarettes or on their health impacts and potential risks. Marketing claims vary among
22 manufacturers and vendors.

23
24 *Claims and Chemical Exposures*

25
26 Some public health advocates argue that as a form of harm reduction, e-cigarettes are far safer to
27 use than conventional cigarettes for individuals who do not wish to eliminate their dependence on
28 nicotine. In some cases, e-cigarettes are promoted either as nicotine delivery devices that do not
29 produce the toxins and cancer-causing chemicals found in secondhand smoke or as devices that
30 comply with the spirit of clean indoor air regulations. Some brands claim that e-cigarettes are
31 useful for reducing smoking and are equivalent to nicotine spray and nicotine inhalation NRT
32 formulations for smoking cessation.⁶ Major U.S. distributors maintain they are not promoting
33 e-cigarettes for smoking cessation but emphasize that these products are safer than cigarettes for
34 those who are addicted to or want to use nicotine but no longer want to be exposed to the risks and
35 dangers of smoking cigarettes.⁸

36
37 Given the limited research and pending further testing, it is generally agreed that e-cigarettes have
38 far fewer ingredients, especially carcinogens and toxins, than conventional cigarettes (which have
39 ~600 ingredients and contain or generate more than 40 recognized carcinogens). Although the
40 vapor produced by e-cigarettes emulates tobacco smoke, it is odorless and does not contain tar or
41 other tobacco by-products. It consists largely of propylene glycol which is commonly found in
42 other consumer products, such as deodorants; moisturizing lotions; toothpastes; pharmaceutical
43 products, including some inhalers; and fat-free dairy products. E-cigarette vendors argue that
44 because the inhaled substance is a vapor and not derived from combustion, the vast majority of
45 harmful products derived from smoking (and secondhand smoke) are not produced and therefore
46 are not concerns with the use of this product. However, the lack of product testing does not permit
47 the conclusion that they do not produce any harmful products, even if they produce fewer
48 dangerous substances than conventional cigarettes.

49

1 Inhaled Nicotine-Containing Devices Used for Smoking Cessation

2
3 One inhaled nicotine-delivery device already in use for cessation is the Nicotrol® Inhaler (known
4 as the Nicorette® inhaler outside of the U.S.). This device consists of a mouthpiece and a plastic
5 cartridge delivering 4 mg of nicotine from a porous plug containing 10 mg nicotine. The cartridge
6 is inserted into the mouthpiece prior to use and need not be inhaled deeply since the medication
7 works in the mouth and throat, not in the lungs. Nicotine is released when air is inhaled through
8 the device. The Nicotrol® Inhaler is approved as an effective aid to smoking cessation for the
9 relief of nicotine withdrawal symptoms and as part of a comprehensive behavioral smoking
10 cessation program. It is marketed as a safe alternative to smoking during the cessation process.⁹
11 The recommended period of use may extend up to six months.

12
13 The Council was unable to identify any independently generated articles on e-cigarettes or inhaled
14 nicotine delivery devices other than the extensive literature on the Nicotrol® Inhaler and a
15 chemical analysis of one brand of e-cigarettes conducted by Demokritas, a publicly funded
16 research institute based in Greece. Controlled studies on the use of e-cigarettes in smoking
17 cessation or their effects on population use of tobacco products have not been published.

18
19 Apart from the FDA's analysis, the most comprehensive published study of e-cigarettes was
20 conducted by Health New Zealand, Ltd. on Ruyan® e-cigarettes, although the study was funded by
21 the manufacturer.¹⁰ This study reviewed the existing literature on propylene glycol and its effects
22 on humans and catalogued a variety of chemical studies conducted by different laboratories on the
23 contents of e-cigarette cartridges, vapors, and mists, as well as an analysis of systemic carbon
24 dioxide concentrations in users. Each puff contains one-third to one-half the nicotine in a tobacco
25 cigarette; trace amounts of tobacco-specific nitrosamines and some other toxins are formed, but, in
26 general, the product was considered a safer alternative to smoking conventional cigarettes. A
27 preliminary report of a randomized crossover trial funded by Ruyan, comparing the Ruyan®
28 e-cigarette containing 16 mg of nicotine with placebo capsules and the Nicorette® inhaler, found
29 that the e-cigarette was as effective in reducing craving and other withdrawal effects as the inhaler,
30 was well-tolerated, and had few adverse effects.¹¹ A report of a small study funded by the National
31 Cancer Institute and conducted at Virginia Commonwealth University, however, concluded that e-
32 cigarettes failed to deliver sufficient nicotine to eliminate craving or to significantly increase
33 plasma nicotine concentrations with every puff.¹²

34
35 The FDA study of e-cigarettes used the Nicotrol® Inhaler as a control. Analysis of two brands of
36 e-cigarettes confirmed their ability to deliver nicotine (in one case, twice as much as the control
37 inhaler), and that the product contained detectable levels of known carcinogens and toxic chemicals
38 (i.e., diethylene glycol, an ingredient used in antifreeze; small amounts of tobacco-specific
39 nitrosamines; and certain other tobacco-specific impurities that may be harmful). The FDA also
40 determined that: (1) some samples labeled as nicotine-free contained measurable amounts; (2)
41 cartridges with the same labeled nicotine content emitted markedly different amounts of nicotine
42 with each puff; and (3) products exhibited inconsistent or lack of quality control processes in
43 product manufacturing.^{2,3} Most recently, Demokritas conducted a similar analysis of the
44 Nobacco® e-cigarette with similar findings.¹³

45 *FDA Advisories*

46
47
48 As a result of its study and examination of other evidence, the FDA issued a consumer health
49 warning regarding e-cigarettes expressing concern that:

- 1 • e-cigarettes can increase nicotine addiction among young people and their use may
- 2 lead to experimenting with other tobacco products;
- 3 • these products may contain ingredients known to be toxic to humans;
- 4 • clinical studies about product safety and efficacy for their intended use have not been
- 5 submitted; and
- 6 ▪ consumers have no way of knowing the doses they are inhaling, the types or
- 7 concentrations of potentially harmful chemicals, or if e-cigarettes are safe for their
- 8 intended use.¹⁴
- 9

10 Furthermore, some of these products are available in flavors such as strawberry, chocolate, and
11 mint that may appeal to young people.

12 13 E-CIGARETTES AND SMOKING CESSATION

14
15 Due to the lack of rigorous chemical and animal studies, as well as clinical trials on commercially
16 available e-cigarettes, neither their value as therapeutic aids for smoking cessation nor their
17 “safety” as cigarette replacements is established and remains speculative. Although one
18 manufacturer advertises that “Millions of smokers have become smoke-free” with the use of its
19 product,⁵ evidence is lacking that these products are effective clinical cessation instruments.
20 Manufacturers of e-cigarettes have not submitted the requisite applications for FDA approval of
21 these products for smoking cessation.

22
23 Nicotrol® has been studied for its effectiveness as a NRT and is approved for clinical use.
24 Fagerstrom and colleagues conducted several studies evaluating the effects of this inhaler on
25 smokers and found that it decreased the number of cigarettes smoked by 86% and reduced exhaled
26 carbon monoxide by 47%, with no decrease in effect over time.¹⁵ Even where cigarette smoking
27 continued, nicotine concentrations did not rise, and adverse reactions were not apparent in
28 Nicorette® users.¹⁶

29
30 The use of inhalers as nicotine delivery devices has a number of advantages over cigarettes, apart
31 from containing considerably fewer toxins. Because absorption occurs primarily via the mucosa of
32 the oral cavity, arterial nicotine concentrations rise more slowly and to lower peak levels than with
33 cigarettes. Therefore, the impact to the lungs is minimal, and the arterial nicotine concentration
34 spike that occurs with cigarette smoking is avoided, thus decreasing the likelihood for abuse.¹⁷
35 Although the absorption of nicotine via an inhaler requires more puffing, as with all NRT
36 formulations, the extent of nicotine absorption is sufficient to prevent smoking relapse by reducing
37 withdrawal symptoms and the craving associated with abrupt smoking cessation. Despite their
38 cigarette-like appearance and their association with usage behaviors that smokers typically
39 associate with the sensory and ritual elements of smoking, little treatment dependence or abuse has
40 been reported with inhalers.¹⁸ In clinical trials, inhalers appear similar to cigarette smoking in
41 levels of satisfaction and reductions in urges to smoke.¹⁹ These features can make inhalers
42 attractive to those who are not ready to quit but are interested in changing their smoking behaviors.
43 Inhaler users also minimize other harms including significant decreases in exhaled carbon
44 monoxide, reduced risk markers for cardiovascular disease, and only minor use-related adverse
45 events, such as throat irritation and cough. Therefore, it is established that the nicotine inhaler can
46 help smokers who are unable or unwilling to quit to reduce daily cigarette consumption, which may
47 provide some (relative) health benefits and further promote quitting.²⁰

48

1 Nicotine Replacement Therapy

2
3 A systematic review of clinical research on nicotine inhalers and other forms of NRT concluded
4 that all forms of NRT are associated with more frequent and successful quit attempts.²¹ The
5 available evidence indicates no overall differences in the effectiveness of different NRT
6 formulations, although heavy smokers may need higher doses of NRT. Furthermore, NRT works
7 without additional counseling and does not need to be prescribed by a physician. The use of NRT
8 does not appear to increase the risk for heart attacks; however, it is possible that the results
9 observed in clinical trials and in smoking cessation programs may differ at the population level.

10
11 Another systematic review evaluated the ability of NRT to assist in reducing harms from continued
12 tobacco use.²² Although use of nicotine gum and/or inhalers significantly reduced daily cigarette
13 use by 50% compared with placebo, only a small percentage in either the treatment or control
14 groups successfully sustained a reduction of 50% or more in cigarette use. In addition, reductions
15 in the markers of exposure to tobacco smoke (levels of carbon monoxide and cotinine) did not
16 decline accordingly. The authors concluded the evidence is insufficient to support the use of NRT
17 interventions designed to help smokers reduce, but not quit, tobacco use and that the degree of
18 health benefit is uncertain.

19
20 Research on the likelihood that smokers, independent of health care settings, would use NRT for
21 cessation has demonstrated that the form of nicotine delivery impacts use. One study found that
22 use was highest for the patch, lower for gum, and very low for the spray and the inhaler; user
23 embarrassment may play a role in lower use of the inhaler.²³ A recent study of non-combustible,
24 reduced-exposure tobacco products intended to reduce the harm associated with smoking, showed
25 that the products decreased the exposure to many of the toxicants found in cigarettes but failed to
26 suppress tobacco abstinence symptoms as effectively as combustible products.²⁴ Although the only
27 non-tobacco derived nicotine delivery device used in this study was a nicotine lozenge, the results
28 suggest that the viability of inhalers as a mass marketed, over-the-counter instrument for either
29 harm reduction or cessation may depend on their ability to deliver nicotine levels equivalent to
30 cigarettes, rather than merely being sufficient to reduce withdrawal symptoms and craving (as is
31 the case with inhalers). This, of course, would also affect their widespread use for cessation
32 purposes.

33
34 On a population-wide basis, a strong possibility exists that e-cigarettes would not be used by large
35 numbers of smokers for either cessation or for harm reduction purposes, although concentrated
36 marketing efforts might influence their use by smokers. At this time, and despite over-the-counter
37 availability of some forms of NRT, less than one in five smokers use NRT in their efforts to quit.²⁵
38 A variety of explanations has been advanced for this behavior: (1) inadequate dosage strengths and
39 formulations of available NRTs; (2) smokers' perceptions that they are costly; (3) purchase age
40 restrictions; (4) concerns of smokers about the safety and efficacy of NRTs due in part to provider
41 misinformation or lack of knowledge; and (5) failure of providers to actively recommend or
42 mention NRT use for smoking cessation. Smoker's preferences for cigarettes as their means to
43 obtain nicotine also plays a role despite the fewer hazards of inhalers.²⁶ A recent survey of
44 California smokers found that 76% expressed no interest in replacing smoking with a tobacco
45 substitute, although smokers with past or current quit attempts were more receptive.²⁷ On the other
46 hand, estimates of the net public health gains from replacing cigarettes with nicotine inhalers
47 support the view that this approach could be a feasible tobacco control strategy; the possible
48 adverse health effects and the risks must be studied and the goals of such a strategy would need to
49 be clearly defined.²⁸

1 *Implications for the Marketing of e-Cigarettes*

2
3 Certainly, a strong possibility exists that the size of the nicotine dependent population could grow –
4 especially if promotions for e-cigarettes approach the magnitude used for other consumer products.
5 Promoting their use in places where smoking is not allowed implies that users need not have any
6 intention of quitting and that the use of e-cigarettes may, in fact, be added on to smoking cigarettes.
7 This pattern of use could either lower or raise a smoker’s systemic nicotine concentration and
8 further reinforce nicotine dependence. In addition, claims that e-cigarettes are safer than tobacco
9 products might also imply that they are desirable for those seeking the effects of nicotine, even if
10 they are not currently smokers.

11
12 Depending on marketing strategies, and in the absence of regulation, e-cigarettes might be
13 marketed to youths. Certainly, much of the promotional literature implies that few risks exist for
14 nicotine dependence or for other hazards attributable to nicotine exposure, including coronary
15 artery disease, acute ischemic events, hypertension, stroke, and use by minors or women who are
16 pregnant.

17
18 Given the absence of a regulatory framework for their manufacture and sale, commercial brands of
19 e-cigarettes probably vary widely in their actual nicotine content and delivery and in the presence
20 of other ingredients. These variables will affect the extent to which the use of e-cigarettes satisfies
21 smokers’ cravings or staves off withdrawal. If, for example, e-cigarettes were used as supplements
22 to smoking in order to stave off withdrawal when individuals are in places where tobacco use is not
23 allowed, their impacts might be very different. At this time it is not established what the public
24 health/population-level impacts of wide distribution of pure nicotine delivery devices would be, nor
25 do we know if they will work at a population level as effective smoking cessation aids.

26 CURRENT REGULATIONS

27
28 In 2008, the World Health Organization (WHO) noted that:

29
30
31 “Contrary to what some marketers of the electronic cigarette imply in their advertisements, the
32 WHO does not consider it to be a legitimate therapy for smokers trying to quit. WHO knows
33 of no evidentiary basis for the marketers’ claim that the electronic cigarette helps people quit
34 smoking. Indeed, as far as WHO is aware, no rigorous peer-reviewed studies have been
35 conducted showing the electronic cigarette is a safe effective nicotine replacement therapy.”²⁹

36
37 The WHO statement did not discount the possibility that e-cigarettes could be useful as a smoking
38 cessation aid but reaffirmed that clinical studies and toxicity analyses need to be done within a
39 proper regulatory framework. Canada, however, fully banned the devices in March 2009
40 (http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2009/2009_53-eng.php).

41
42 In early 2009, the FDA issued an import alert prohibiting e-cigarettes from entering the country on
43 the basis that they were unapproved drug-device combinations. Although the FDA has the
44 authority to regulate tobacco products, two distributors of electronic cigarettes sought an injunction
45 against the import ban claiming that their products were cigarette replacements and thus not
46 governed by the FDA.³⁰ In January 2010, the U.S. District Court for the District of Columbia
47 granted such an injunction, which the FDA appealed. In March 2010, the U.S. Court of Appeals
48 agreed to permit the FDA’s continued import ban while it considers the FDA appeal from the lower
49 court ruling. The court went out of its way in its brief ruling to suggest that the FDA was correct in
50 declaring the product illegal, noting that “appellants (FDA) have satisfied the stringent standards
51 required for a stay pending appeal.” Oral arguments are to be heard this fall.

1 Oregon and California Attorneys General have filed lawsuits against Smoking Everywhere, Inc. for
2 marketing to children and false health claims. Smoking Everywhere, Inc. also has argued in these
3 cases that e-cigarettes are tobacco products under the Family Smoking Prevention and Tobacco
4 Control Act and, as such, the Oregon and California AG's do not have the authority to bring those
5 lawsuits.

6
7 Final decisions about the regulation of e-cigarettes may take some time and are likely to be
8 adjudicated by the courts.

9
10 CONCLUSION

11
12 E-cigarettes are not comparable to FDA-approved nicotine-delivery devices that have been shown
13 to help people quit smoking. At this time, their dosage, manufacture, and ingredients are not
14 consistent nor are the products clearly labeled, thus making their use by smokers wanting to quit an
15 uninformed proposition. More importantly, the manufacturers of e-cigarettes have not submitted
16 the requisite applications for FDA approval of these products for smoking cessation. Only one
17 small clinical trial, funded by an e-cigarette manufacturer has been published on their efficacy as a
18 smoking substitute (but not as a cessation aid).

19
20 The FDA has rejected claims by e-cigarette makers and distributors that their devices are safer than
21 real cigarettes and mitigate the harm of smoking. While some distributors have implied that their
22 products help people quit smoking tobacco products, the agency views them as unapproved
23 synthetic nicotine delivery devices with unknown safety and efficacy. Whether e-cigarettes can
24 safely help people quit smoking also is unknown, but with their fruit and candy flavors, they have a
25 clear potential to entice new smokers, especially teens. In addition, because of the unregulated
26 dosing of nicotine, they clearly can be addictive.

27
28 It is evident from what little information we have that the concentration levels of the nicotine and
29 other compounds are variable, and that there are toxins and carcinogens present. Thus, controlled
30 trials and test market studies are needed to determine if they are safe and effective as a smoking
31 cessation device as is being reported in the media and on the manufacturers' Web sites.³¹ As most
32 clean indoor air ordinances are written, it is likely that e-cigarettes can and will be used in smoke-
33 free environments. Whether this would weaken the health benefits of such antismoking regulations
34 is not known. Additionally, it is not established that e-cigarettes will serve as an effective means
35 for harm reduction and as an additional tool for tobacco control. In fact, it is not inconceivable that
36 the number of nicotine dependent individuals could increase. Thus far, much of the discussion
37 about the use of e-cigarettes has been based on advocacy for their use, and/or assumptions of
38 population-wide benefits which have yet to be demonstrated. Similar to concerns regarding the
39 manufacture and sale of tobacco products, the actual content, performance as a nicotine delivery
40 device, safety, and purity of e-cigarettes is largely unknown.

41
42 RECOMMENDATIONS

43
44 The Council on Science and Public Health recommends that the following statements be adopted
45 and the remainder of the report be filed:

46
47 Our American Medical Association urges that:

- 48
49 1. E-cigarettes be classified as (nicotine) drug delivery devices and should be subject to FDA
50 regulation with appropriate standards for identity, strength, purity, packaging, and labeling
51 with instructions and contraindications for use, including age of the user. (New HOD Policy)

- 1 2. State legislatures prohibit the sales of e-cigarettes and all other nicotine devices that are not
2 FDA-approved. (New HOD Policy)
3
- 4 3. As currently marketed, e-cigarettes be included in smokefree laws but separately
5 defined from tobacco products. (New HOD Policy)
6
- 7 4. Policy D-490.975, “Study of Appropriate Use of Electronic Cigarettes in Smoking Cessation
8 Programs,” be rescinded. (Rescind HOD Policy)

Fiscal Note: Less than \$500

REFERENCES

1. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008; pp.7-8.
2. Division of Pharmaceutical Analysis, Center for Drug Evaluation and Research. Evaluation of e-cigarettes. Report to the Office of Compliance, Division of New Drugs and Labeling Compliance, Food and Drug Administration, Dept. of Health and Human Services. May 4, 2009. <http://www.fda.gov/downloads/Drugs/ScienceResearch/UCM173250.pdf>. Accessed January 22, 2010.
3. U.S. FDA. Public Health Focus - Summary of results: laboratory analysis of electronic cigarettes conducted by FDA. Washington, DC: U.S. Food and Drug Administration, July 22, 2009. <http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm173146.htm>. Accessed January 19, 2010.
4. Wollscheid KA, Kremzner ME. Electronic cigarettes: safety concerns and regulatory issues. *Am J Health-Syst Pharm.* 2009;66:1740-1742.
5. “Easy As Step 1, 2, 3 E-Cigarette” Website: <http://www.electroniccigarette124.com/buy>. Accessed January 13, 2010.
6. Digital Ciggs. Digital cigarettes – 10 frequently asked questions about electronic cigarettes. November 15, 2009. <http://digitalciggs.com>. Accessed January 11, 2010.
7. Memorandum Opinion, *Smoking Everywhere, Inc. and Sottera, Inc. d/b/a NJOY v. U.S. Food and Drug Administration.* (DC Cir, 2010) Civil Case No. 09-771(RJL).
8. DeNoon DJ. E-cigarettes under fire. No-smoke electronic cigarettes draw criticism from FDA, Medical Groups. WebMD Feature. April 13, 2009. <http://www.webmd.com/smoking-cessation/features/ecigarettes-under-fire>. Accessed January 11, 2010.
9. WebMD Drug Information from First DataBank. FDA Approved nicotine inhaler – Pfizer’s Nicotrol Inhaler. Nicotrol Inhl. <http://www.webmd.com/drugs/drug-5204-nicotrol+inhl.aspx>. Accessed August 17, 2009.
10. Laugesen M. Safety Report on the Ruyan® e-cigarette cartridge and inhaled aerosol. Christchurch, New Zealand: Health New Zealand Ltd, October 21, 2008. Available at: www.healthnz.co.nz.
11. Bullen CR, McRobbie H, Thornley S, Chen X, Glover M, Laugesen. Effect of an electronic nicotine inhaler on cravings, withdrawal, acceptability and nicotine delivery. Abstract of poster session presented at the 2009 Joint Conference of the Society for Research on Nicotine and Tobacco (SRNT) and SRNT-Europe, Dublin, Ireland April 27-30, 2009. http://www.srnt.org/meeting/2009/pdf/2009_Poster_Sessions.pdf. Accessed January 14, 2010.
12. Eisenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. *Tobacco Control.* 2010;19:87-88.

13. Flouris AD, Oikonomou DN. Personal View. Electronic cigarettes: miracle or menace? *BMJ*. 2010;340:c311.
14. FDA Consumer Health Information. FDA warns of health risks posed by e-cigarettes. Washington, DC: U.S. Food and Drug Administration, July 2009. www.fda.gov/consumer. Accessed January 16, 2010.
15. Fagerström KO, Hughes JR, Callas PW. Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. *Nicotine Tob Res*. 2002;4(Suppl 2):S141-145.
16. Fagerström KO, Hughes JR. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. *Nicotine Tob Res*. 2002;4(Suppl 2):S73-79.
17. Lunell E, Molander L, Ekberg K, Wahren J. Site of nicotine absorption from a vapour inhaler-comparison with cigarette smoking. *Eur J Clin Pharmacol*. 2000;55:737-741.
18. Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. *Clin Pharmacokinet*. 2001;40:661-684.
19. Caldwell B, Dickson S, Burgess C, et al. A pilot study of nicotine delivery to smokers from a metered-dose inhaler. *Nicotine Tob Res*. 2009;11:342-347. [Epub ahead of print, Apr 3]
20. Rennard SI, Glover ED, Leischow S, et al. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. *Nicotine Tob Res*. 2006;8:555-564.
21. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev*. 2008;(1):CD000146. Updated November 2007.
22. Tead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. *Cochrane Database Syst Rev*. 2007;(3):CD005231.
23. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. *Arch Intern Med*. 1999;159:2033-2038.
24. Cobb CO, Weaver MF, Eissenberg T. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. *Tob Control*. 2009 [Epub ahead of print, Apr 2]
25. Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior and thus their availability has not had a measurable impact on population smoking behavior trends. *Annu Rev Public Health*. 2005;26:583-599.
26. Sumner W. Estimating the health consequences of replacing cigarettes with nicotine inhalers. *Tob Control*. 2003;12:124-132.
27. Timberlake DS. Are smokers receptive to using smokeless tobacco as a substitute? *Prev Med*. 2009;49:229-232.

28. Kunze U, Schoberberger R, Schmeiser-Rieder A, Groman E, Kunze M. Alternative nicotine delivery systems (ANDS)--public health-aspects. *Wien Klin Wochenschr.* 1998;110:811-816.
29. World Health Organization. "Marketers of electronic cigarettes would halt unproved therapy claims" Geneva, Switzerland: WHO Tobacco Free Initiative, September 19, 2008. <http://www.who.int/mediacentre/new/release/2008/pr34/en/print.html>. Accessed January 11, 2010.
30. Duff Wilson. Judge Orders FDA. to stop blocking imports of e-cigarettes from China. *New York Times.* January 14, 2010. <http://www.nytimes.com/2010/01/15/business/15smoke.html>. Accessed January 22, 2010.
31. Sumner W. Permissive nicotine regulation as a complement to traditional tobacco control. *BMC Public Health.* 2005;5:18.